WO2020256464A1 - Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production - Google Patents
Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production Download PDFInfo
- Publication number
- WO2020256464A1 WO2020256464A1 PCT/KR2020/007962 KR2020007962W WO2020256464A1 WO 2020256464 A1 WO2020256464 A1 WO 2020256464A1 KR 2020007962 W KR2020007962 W KR 2020007962W WO 2020256464 A1 WO2020256464 A1 WO 2020256464A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ethanol
- inflammatory
- gastritis
- fraction
- extract
- Prior art date
Links
- 235000003276 Apios tuberosa Nutrition 0.000 title claims abstract description 99
- 239000000284 extract Substances 0.000 title claims abstract description 64
- 206010017856 Gastritis alcoholic Diseases 0.000 title claims abstract description 48
- 201000005988 alcoholic gastritis Diseases 0.000 title claims abstract description 48
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 241001098044 Apios americana Species 0.000 title claims abstract 13
- 229940124597 therapeutic agent Drugs 0.000 title abstract description 3
- 230000003449 preventive effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 92
- 239000002031 ethanolic fraction Substances 0.000 claims abstract description 58
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 56
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 44
- 239000002904 solvent Substances 0.000 claims abstract description 25
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 157
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 116
- 208000007882 Gastritis Diseases 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 230000036541 health Effects 0.000 claims description 22
- -1 7,2',4'-trihydroxy-5-methoxyisoflavone-4' -O Chemical class 0.000 claims description 21
- 235000013376 functional food Nutrition 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 16
- 201000005917 gastric ulcer Diseases 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 16
- 230000002496 gastric effect Effects 0.000 claims description 14
- 230000006378 damage Effects 0.000 claims description 13
- 208000000491 Tendinopathy Diseases 0.000 claims description 12
- 206010043255 Tendonitis Diseases 0.000 claims description 12
- 238000005194 fractionation Methods 0.000 claims description 12
- 201000004415 tendinitis Diseases 0.000 claims description 12
- 238000003818 flash chromatography Methods 0.000 claims description 10
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- GSSOWCUOWLMMRJ-UHFFFAOYSA-N 2'-hydroxygenistein Chemical compound OC1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O GSSOWCUOWLMMRJ-UHFFFAOYSA-N 0.000 claims description 8
- 230000006872 improvement Effects 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 230000007815 allergy Effects 0.000 claims description 7
- 206010025135 lupus erythematosus Diseases 0.000 claims description 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 6
- 206010003645 Atopy Diseases 0.000 claims description 6
- 206010010741 Conjunctivitis Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 208000001640 Fibromyalgia Diseases 0.000 claims description 6
- 201000005569 Gout Diseases 0.000 claims description 6
- 201000002481 Myositis Diseases 0.000 claims description 6
- 206010030113 Oedema Diseases 0.000 claims description 6
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 6
- 206010033078 Otitis media Diseases 0.000 claims description 6
- 201000007100 Pharyngitis Diseases 0.000 claims description 6
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 6
- 206010037660 Pyrexia Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 208000023652 chronic gastritis Diseases 0.000 claims description 6
- 206010009887 colitis Diseases 0.000 claims description 6
- 201000003146 cystitis Diseases 0.000 claims description 6
- 208000014617 hemorrhoid Diseases 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 201000008383 nephritis Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 201000001245 periodontitis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 206010039083 rhinitis Diseases 0.000 claims description 6
- 230000009897 systematic effect Effects 0.000 claims description 6
- 206010044008 tonsillitis Diseases 0.000 claims description 6
- 206010060968 Arthritis infective Diseases 0.000 claims 4
- 206010019133 Hangover Diseases 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 17
- 244000176051 Apios tuberosa Species 0.000 description 84
- 235000019441 ethanol Nutrition 0.000 description 50
- 230000000694 effects Effects 0.000 description 19
- 235000013305 food Nutrition 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 238000009472 formulation Methods 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 210000001156 gastric mucosa Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 241000913828 Apios Species 0.000 description 5
- 239000012223 aqueous fraction Substances 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000000454 talc Substances 0.000 description 5
- 229910052623 talc Inorganic materials 0.000 description 5
- 235000012222 talc Nutrition 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 235000018122 Helianthus giganteus Nutrition 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 241000775685 Orogenia linearifolia Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- JHSUMRFUODHFLH-UHFFFAOYSA-N COc(cc(cc1OC=C2c(ccc(OC(C(C3O)O)OC(CO)C3O)c3)c3O)OC(C(C3O)O)OC(CO)C3O)c1C2=O Chemical compound COc(cc(cc1OC=C2c(ccc(OC(C(C3O)O)OC(CO)C3O)c3)c3O)OC(C(C3O)O)OC(CO)C3O)c1C2=O JHSUMRFUODHFLH-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AVGPOAXYRRIZMM-UHFFFAOYSA-N D-Apiose Natural products OCC(O)(CO)C(O)C=O AVGPOAXYRRIZMM-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-LJJLCWGRSA-N D-apiofuranose Chemical compound OC[C@@]1(O)COC(O)[C@@H]1O ASNHGEVAWNWCRQ-LJJLCWGRSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N D-apiofuranose Natural products OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ONYFNWIHJBLQKE-ZETCQYMHSA-N N(6)-acetimidoyl-L-lysine Chemical compound CC(=N)NCCCC[C@H](N)C(O)=O ONYFNWIHJBLQKE-ZETCQYMHSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- VQWFNAGFNGABOH-UHFFFAOYSA-K chromium(iii) hydroxide Chemical compound [OH-].[OH-].[OH-].[Cr+3] VQWFNAGFNGABOH-UHFFFAOYSA-K 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229940065004 poison ivy extract Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229930010796 primary metabolite Natural products 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Definitions
- the present invention relates to the use of a fraction of Apios americana tuber extract having anti-inflammatory activity as a prophylactic or therapeutic agent for alcoholic gastritis, and a method for preparing the same, and more particularly, to an anti-inflammatory comprising Apios americana tuber fraction extracted and fractionated with a specific solvent A composition, a composition for preventing, ameliorating or treating an inflammatory disease or alcoholic gastritis comprising the anti-inflammatory composition, a method for preventing or treating an inflammatory disease or alcoholic gastritis using the anti-inflammatory composition, an anti-inflammatory agent, preventing or treating an inflammatory disease or alcoholic gastritis
- the use of the ethanol fraction of the ethanol extract of Apios americana tuber in the manufacture of a medicament for the preparation and a method of preparing the fraction having anti-inflammatory activity are provided.
- Nitric oxide is an important intracellular and intercellular signaling molecule involved in regulating various physiological mechanisms in the immune system. Nitric oxide reacts with superoxide to produce peroxynitrite ions, and the generated ions induce excessive inflammatory activity, sepsis, ulcerative colitis, arthritis, and lupus. (systemic lupus erythematosus, SLE) and Sjogren's syndrome (SS) are known to cause diseases. Reactive oxygen species (ROS) and nitric oxide (NO) play a very important physiological role as intermediate mediators in the signaling process.
- ROS reactive oxygen species
- NO nitric oxide
- inflammatory regulators in cells are inflammatory cells such as macrophages in vivo by inducible nitric oxide synthase (iNOS) or cyclo-oxygenase-2 (COX-2).
- Inflammatory mediators such as nitric oxide (NO), prostaglandin (PG), interleukin-1 beta (IL-1 ⁇ ), and tumor necrosis factor-alpha; TNF- ⁇ ) and cytokines are produced in large quantities.
- Non-steroidal anti-inflammatory drugs which are widely used as treatments for most inflammatory diseases, are prostaglandin from arachidonic acid called cyclooxygenase (COX). By inhibiting the enzyme activity involved in the biosynthesis of, it exhibits anti-inflammatory action. In addition to the main therapeutic action, it causes serious side effects such as gastrointestinal disorders, liver disorders, and renal disorders, so there are restrictions in long-term use.
- COX cyclooxygenase
- Alcoholic gastritis one of the inflammatory diseases, refers to a condition in which the gastric mucosa is damaged by chronic irritation caused by alcohol. Alcoholic gastritis is difficult to digest and sometimes complains of a sore sensation, but most do not have any special symptoms, and then serious symptoms are found through endoscopy and ultrasound. Chronically drinking alcohol causes related diseases by damaging not only gastritis, but also the pancreas or liver, and also increases the risk of esophageal cancer, stomach cancer, and colon cancer.
- Alcohol stimulates the cells of the stomach wall to increase acid secretion, and excessive alcohol intake causes swelling of the gastric mucosa, causing bleeding and inducing the production of inflammatory cells. .
- necrosis or apoptosis due to oxidative stress, the gastric mucosa is damaged, and gastric bleeding occurs.
- Korean Patent Application Publication No. 10-2009-0046425 composition for preventing or treating gastritis or gastric ulcer containing Cheonma extract
- Korean Patent Registration No. 10-1091025 non-steroidal anti-inflammatory agent containing Bokbunja extract
- Korean Patent Laid-Open Publication No. 10-2012-0051904 Gastritis and gastric ulcer treatment composition containing poison ivy extract
- Korean Patent No. 10-1204981 Gao-seon sap And a composition for preventing and treating gastric ulcers
- Apios ( Apios americana Medikus) is a vine perennial herb belonging to the legume family, and its origin is in temperate and subtropical regions in eastern North America, and is also called'Indian potato' because it has been eaten by North American Indians since ancient times.
- Apios was first introduced to Japan in Asia and used as a health food, but recently, it has been introduced to Korea and is actively cultivated as a new farm income crop.
- Apios forms flowers and leaves in the upper part and tubers in the basement part, of which tubers are mainly used for food.
- the main components of apios are starch, protein, and moisture, and in addition, saponin, calcium, iron, dietary fiber, and the like are contained in large amounts, and are widely used as natural calcium agents.
- Korean Laid-Open Patent No. 10-2018-0095193 discloses the anticancer activity of Apios Americana extract
- Korean Laid-Open Patent No. 10-2015-0132616 discloses Apios extract or fermented extract. It has been disclosed that RAW 264.7 cells exhibit an immunity enhancing effect by increasing the expression of a gene or protein of NO, an immune enhancing factor, in RAW 264.7 cells.
- the present inventors confirmed that the fraction obtained by fractionating Apios americana tuber extract with a specific solvent exhibits an activity of inhibiting NO production in LSP-induced RAW 264.7 cells, and completed the present invention.
- An object of the present invention is to provide the use of the ethanol fraction of the ethanol extract of Apios Americana tuber in the preparation of an anti-inflammatory composition and/or an anti-inflammatory agent comprising a fraction of Apios Americana tuber extract.
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating inflammatory diseases and/or a health functional food composition for preventing or improving inflammatory diseases, including a fraction of Apios Americana tuber extract.
- Another object of the present invention is a method for preventing or treating inflammatory diseases using a fraction of Apios Americana tuber extract and/or ethanol of Apios Americana tuber ethanol extract in the manufacture of a medicament for the prevention or treatment of inflammatory diseases It is to provide the use of fractions.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of alcoholic gastritis, and/or a health functional food composition for the prevention or improvement of alcoholic gastritis, comprising a fraction of Apios Americana tuber extract.
- Another object of the present invention is a method for preventing or treating alcoholic gastritis using a fraction of Apios Americana tuber extract and/or ethanol of Apios Americana tuber ethanol extract in the manufacture of a medicament for the prevention or treatment of alcoholic gastritis. It is to provide the use of fractions.
- Another object of the present invention is to provide a method for preparing a fraction of Apios americana tuber extract having anti-inflammatory activity.
- the present invention provides an anti-inflammatory composition comprising an ethanol fraction of an ethanol extract of Apios Americana tubers.
- the ethanol extract may be obtained by using 50 (v/v)% to 90 (v/v)% ethanol as an extraction solvent.
- the ethanol fraction is 50(v/v)% to 90(v/v)% ethanol extract to 5(v/v)% to 35(v/v)% ethanol. It may be obtained by fractionation.
- the anti-inflammatory composition is 2′-hydroxy-5-methoxygenistein-7,4′- O- ⁇ -D-diglucopyranoside, 2′-hydroxy genistein -7,4'- O - ⁇ -D- gluconic di nose side Llano, 2'-hydroxy-genistein -7- O - ⁇ -D- thio Zen rainy side, and 7,2 ', 4'-trihydroxy It may contain one or more compounds selected from the group consisting of -5-methoxyisoflavone-4'- O- ⁇ -D-glucopyranoside.
- the present invention also provides the use of the ethanol fraction of the ethanol extract of Apios Americana tubers in the preparation of anti-inflammatory agents.
- the present invention provides a pharmaceutical composition for preventing or treating inflammatory diseases and/or a health functional food composition for preventing or improving inflammatory diseases, including the anti-inflammatory composition described above.
- the present invention also provides a method for preventing or treating an inflammatory disease, comprising administering a composition comprising an ethanol fraction of ethanol extract of Apios Americana tubers to an individual in need thereof.
- the present invention also provides the use of the ethanol fraction of Apios Americana tuber ethanol extract in the manufacture of a medicament for preventing or treating inflammatory diseases.
- the inflammatory disease may be a nitrogen monoxide (NO) mediated disease.
- NO nitrogen monoxide
- the nitrogen monoxide (NO) mediated inflammatory disease is edema, dermatitis, allergy, atopy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn Disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatoid fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, peri-shoulderitis, tendinitis, tendonitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrom And it may be selected from the group consisting of multiple sclerosis.
- the present invention provides a pharmaceutical composition for preventing or treating alcoholic gastritis, and/or a health functional food composition for preventing or improving alcoholic gastritis, including the anti-inflammatory composition described above.
- the present invention also provides a method for preventing or treating alcoholic gastritis, comprising administering a composition comprising an ethanol fraction of an ethanol extract of Apios Americana tubers to an individual in need thereof.
- the present invention also provides the use of the ethanol fraction of Apios Americana tuber ethanol extract in the manufacture of a medicament for preventing or treating alcoholic gastritis.
- the alcoholic gastritis may be selected from the group consisting of alcohol-induced acute gastric mucosal damage, gastric ulcer, acute gastritis, and chronic gastritis.
- the present invention also provides a method for preparing a fraction of Apios americana tuber extract comprising the following steps:
- the ethanol of step d) may be ethanol having a concentration of 5 (v/v)% to 35 (v/v)%.
- the systemic fractionation in step d) may be performed using flash chromatography.
- the fraction prepared by the above preparation method is 2′-hydroxy-5-methoxygenistein-7,4′- O- ⁇ -D-diglucopyranoside, 2 '-Hydroxygenistein-7,4'- O - ⁇ -D-diglucopyranoside, 2'-hydroxygenistein-7- O - ⁇ -D-genthiobioside and 7,2',4' -Trihydroxy-5-methoxyisoflavone-4′- O - ⁇ -D-glucopyranoside may contain one or more compounds selected from the group consisting of.
- the anti-inflammatory composition comprising the ethanol fraction of the ethanol extract of Apios Americana tuber of the present invention exhibits excellent nitric oxide (NO) production inhibitory activity, it is for preventing, improving or treating various inflammatory diseases including alcoholic gastritis. It can be used in medicines, quasi-drugs, health functional foods, cosmetics or feed.
- the present invention is the most environmentally friendly and economical in food processing because ethanol is used as a solvent in the manufacture of fractions, and it is safe for the human body because the resources of food materials are extracted and fractionated.
- 1 is a schematic diagram showing a method for preparing Apios americana tuber extract and each fraction thereof of the present invention.
- FIG. 2 is a graph showing the NO inhibitory activity of the ethanol extract of Apios americana tubers.
- Figure 3 is a graph showing the NO production inhibitory activity of each fraction of the ethanol extract of Apios americana tubers.
- Figures 7a to 7e confirm the effect of improving alcoholic gastritis according to the administration of the ethanol fraction of Apios americana tubers
- Figure 7a is a photograph observed with the naked eye the degree of inflammation of the stomach tissue
- Figures 7b and 7c are histopathological evaluation For hematoxylin & eosin (H&E) staining and PAS staining are shown
- Figures 7d and 7e show the results of evaluating the ulcer index.
- the present inventors have confirmed that unlike the previously known activity of promoting NO production of Apios americana, the fraction of Apios americana tuber extract exhibits an activity of inhibiting NO production in LPS-induced RAW 264.7 cells.
- the present invention provides an anti-inflammatory composition comprising the ethanol fraction of the ethanol extract of Apios Americana tubers.
- Apios americana Medikus used in the present invention is a vine perennial herb belonging to the legume family and is also called an Indian potato.
- the site of Apios Americana used in the composition of the present invention is a tuber in the basement, api Os americana tubers can be purchased commercially, or can be harvested or grown in nature.
- extract refers to an extract obtained by extraction treatment of the Apios americana tubers, more preferably dried Apios americana tubers, a dilution or concentrate of the extract, a dried product obtained by drying the extract, It includes the extract of all formulations that can be formed using the extract itself and the extract, such as the preparation or purified product of the extract, or a mixture thereof.
- the extract of the present invention may be extracted from natural, hybrid or variant plants of Apios americana, and may also be extracted from plant tissue culture.
- the ethanol extract may be obtained by using 50 (v/v)% to 90 (v/v)% ethanol as an extraction solvent, more preferably from 60 (v/v)% to It may be obtained by using 80 (v/v)% ethanol, most preferably 65 (v/v)% to 75 (v/v)% ethanol as an extraction solvent.
- composition of the present invention can be prepared as a solvent extract obtained by extracting the dried Apios americana tubers at least once using the solvent, and then freeze-drying or spray-drying the solvent extract under reduced pressure. I can.
- fraction means a result obtained by performing fractionation in order to separate a specific component or a specific component group from a mixture containing several different constituents.
- the fractionation method for obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
- Non-limiting examples of the fractionation method include a method of obtaining a fraction from the extract by treating an extract obtained by extracting dried Apios americana tubers with a predetermined solvent.
- the type of solvent used to obtain the fraction is ethanol.
- the content of the active ingredient exhibiting anti-inflammatory activity decreases rapidly, and the intended physiological activity may not appear.
- the ethanol fraction is obtained by fractionating 5 (v/v)% to 35 (v/v)% ethanol extract into 10 (v/v)% to 30 (v/v)% ethanol It may be, and most preferably 15 (v/v)% to 25 (v/v)% ethanol extract may be obtained by fractionation.
- an Apios americana extract prepared using 70 (v/v)% ethanol as an extraction solvent is used in water, 20 (v/v)% ethanol, and 100 (v/v). )% ethanol was fractionated and purified for each compartment, and each fraction was treated with LPS-induced macrophage cell line RAW264.7 to confirm the NO production inhibitory effect.
- the composition of the present invention contains a fraction obtained by systematically fractionating the Apios americana extract with water and ethanol as an active ingredient.
- it may be obtained by systematic fractionation of the Apios americana extract with water and 5 (v/v)% to 35 (v/v)% ethanol, and more preferably the Apios americana extract with water and 10 (v /v)% to 30 (v/v)% ethanol, most preferably water and 15 (v/v)% to 25 (v/v)% ethanol may be sequentially obtained by systematic fractionation.
- the present invention also provides the use of the ethanol fraction of the ethanol extract of Apios Americana tubers in the preparation of anti-inflammatory agents.
- the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases and/or a health functional food composition for the prevention or improvement of inflammatory diseases, including the ethanol fraction of Apios Americana tuber ethanol extract.
- the present invention also provides a method for preventing or treating inflammatory diseases, comprising administering a composition comprising an ethanol fraction of ethanol extract of Apios Americana tubers to an individual in need thereof.
- the present invention also provides the use of the ethanol fraction of Apios Americana tuber ethanol extract in the manufacture of a medicament for preventing or treating inflammatory diseases.
- the inflammatory disease may be a nitrogen monoxide (NO) mediated inflammatory disease
- the nitrogen monoxide (NO) mediated inflammatory disease may be edema, dermatitis, allergy, atopy, asthma, conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer.
- Gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatoid fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, tendonitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome (sjogren's syndrom) and multiple sclerosis may be selected from the group consisting of.
- the present invention provides a pharmaceutical composition for the prevention or treatment of alcoholic gastritis and/or a health functional food composition for the prevention or improvement of alcoholic gastritis, including the ethanol fraction of the ethanol extract of Apios Americana tubers.
- the present invention also provides a method for preventing or treating alcoholic gastritis, comprising administering a composition comprising an ethanol fraction of an ethanol extract of Apios Americana tubers to an individual in need thereof.
- the present invention also provides the use of the ethanol fraction of Apios Americana tuber ethanol extract in the manufacture of a medicament for preventing or treating alcoholic gastritis.
- the alcoholic gastritis may be selected from the group consisting of alcohol-induced acute gastric mucosal injury, gastric ulcer, acute gastritis, and chronic gastritis.
- the ethanol fraction of Apios americana tubers remarkably restores gastric tissue damaged by gastritis induced by HCl/EtOH, and has an excellent effect of protecting the mucous layer of the gastric mucosa.
- the pharmaceutical composition of the present invention may additionally include a pharmaceutically acceptable carrier.
- the pharmaceutical composition of the present invention can be prepared in a pharmaceutical formulation using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to a mammal.
- the pharmaceutical composition of the present invention is formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, and sterile injectable solutions according to conventional methods.
- a suitable carrier, excipient, and diluent commonly used in the preparation of the composition may be further included.
- carriers that may be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, and the like, but are not limited thereto.
- it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and these solid preparations contain at least one excipient, such as starch, calcium carbonate, and sucrose. ) Or lactose (lactose), gelatin, etc. are mixed to prepare. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
- Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc., and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to water and liquid paraffin, which are commonly used simple diluents. have.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
- injectable ester such as ethyl oleate
- a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like may be used.
- administering means introducing the pharmaceutical composition of the present invention to a patient by any suitable method.
- the method of administration of the pharmaceutical composition according to the present invention is not particularly limited, and may be followed by a method commonly used in the art.
- the mode of administration is not limited as long as it can reach the target tissue, but may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, or intranasally.
- the pharmaceutical composition according to the present invention may be prepared in various formulations according to the intended administration method.
- the pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount.
- the "pharmaceutically effective amount” means an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type and severity of the individual, age, sex, type of infected virus, drug Activity, sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.
- a typical daily dosage of the pharmaceutical composition according to the present invention may be appropriately selected by a person skilled in the art, and may be administered once or dividedly several times.
- composition of the present invention may be administered daily or intermittently, and the number of administrations per day may be administered once or divided into 2-3 times.
- composition of the present invention may be used alone or in combination with other drug treatments to enhance immunity. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and can be easily determined by a person skilled in the art.
- the pharmaceutical composition of the present invention can be administered to a subject in need of anti-inflammatory activity or to a subject having a nitrogen monoxide (NO) mediated inflammatory disease to suppress an excessive inflammatory response or treat a nitrogen monoxide (NO) mediated inflammatory disease.
- NO nitrogen monoxide
- the term "individual” refers to all animals including humans who have developed or are likely to develop nitrogen monoxide (NO) mediated inflammatory diseases.
- the animals may be mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc. in need of treatment for symptoms similar to humans, but are not limited thereto.
- the present invention provides a quasi-drug composition for preventing or improving inflammatory diseases comprising an ethanol fraction of an ethanol extract of Apios Americana tubers.
- the term "quasi-drug" used in the present invention refers to fibers, rubber products, or the like, which are used for the purpose of treating, alleviating, treating, or preventing diseases of humans or animals, and the action on the human body is weak or does not act directly on the human body, It means something similar to something that is not an instrument or machine.
- an article corresponding to one of the preparations used for sterilization, insecticide, and similar purposes for the prevention of infectious type among the articles used for the purpose of diagnosing, treating, alleviating, treating or preventing human or animal diseases, instruments and machines
- it may refer to an article other than a device, machine, or device among articles that are not devices and are used for the purpose of having a pharmacological effect on the structure and function of humans or animals.
- the quasi-drug may include external skin preparations and personal hygiene products. Specifically, it may be a disinfectant cleaner, shower foam, gagrin, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.
- the quasi-drug composition of the present invention When used as a quasi-drug additive, the composition may be added as it is or may be used together with other quasi-drug or quasi-drug components, and may be appropriately used according to a conventional method.
- the mixing amount of the active ingredient may be appropriately determined according to the purpose of use.
- food used in the present invention refers to meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcohol There are beverages, vitamin complexes, health functional foods, and health foods, and all foods in the usual sense are included.
- the health functional food composition of the present invention includes the form of pills, powders, granules, needles, tablets, capsules or liquids, and as foods to which the composition of the present invention can be added, for example, various foods, such as For example, there are beverages, gum, tea, vitamin complexes, and dietary supplements.
- other ingredients other than those containing the ethanol fraction of the ethanol extract of Apios americana tuber are not particularly limited, and various herbal extracts, food supplements, or It may contain natural carbohydrates and the like as additional ingredients.
- the food additives include food additives conventional in the art, such as flavoring agents, flavoring agents, coloring agents, fillers, stabilizers, and the like.
- Examples of the natural carbohydrate include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
- natural flavoring agents for example, rebaudioside A, glycyrrhizin, etc.
- synthetic flavoring agents sacharin, aspartame, etc.
- the health functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and fillers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid. And salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like. In addition, it may contain flesh for the manufacture of natural fruit juice and fruit juice beverages and vegetable beverages. These components may be used independently or in combination.
- the health supplements include health functional foods and health foods.
- Functional food is the same term as food for special health use (FoSHU), and is a medicine that is processed so that the bioregulatory function effectively appears in addition to nutrition supply, and has high medical effect.
- the term “function (sex)” means obtaining useful effects for health purposes such as controlling nutrients or physiological effects on the structure and function of the human body.
- the food of the present invention can be prepared by a method commonly used in the art, and during the production, raw materials and ingredients commonly added in the art may be added to prepare the food product.
- the formulation of the food may be prepared without limitation as long as it is a formulation recognized as a food.
- the health functional food composition of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage of not having side effects that may occur when taking the drug for a long time by using food as a raw material.
- the present invention also provides a cosmetic composition for preventing or improving inflammatory diseases comprising the ethanol fraction of the ethanol extract of Apios Americana tubers.
- the cosmetic composition may be used as an active ingredient of a functional cosmetic, and the content of the fermented product included in the functional cosmetic is not particularly limited, but may be, for example, 0.01 to 99.9% by weight (w/w)%.
- Functional cosmetics of the present invention may contain the above fractions as an active ingredient, and may additionally contain commonly used cosmetics, for example, glycerol, propylene glycol, 1,3-butylene glycol, sorbitol for water-soluble skin formulations. , Polyethylene glycol, carboxyvinyl polymer, xanthan gum, carboxymethyl cellulose, hydroxyethyl cellulose, hydroxymethyl cellulose, locust bean gum, allantoin, carrageenan, etc.
- Pigments include extender pigments such as titanium dioxide, fine particles of ditanic dioxide, kaolin, nylon powder, talc, sericite, mica, and polymethyl methacrylate, and yellow iron oxide, black iron oxide, red iron oxide, ultramarine, chromium oxide, chromium hydroxide, etc.
- a colored pigment of can be used;
- a moisturizing agent natural moisturizing substances such as 1,3-butylene glycol, concentrated glycerin, ethylene glycol, etc., such as chitin, chitosan, hyaluronic acid, hyaluronic acid, lactic acid, and glycolic acid, may be used;
- a preservative paraoxybenzoic acid esters, imidazolidinyl urea, and the like can be used, as well as one or two or more kinds of the above ingredients according to product characteristics.
- the functional cosmetic may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil , Powder foundation, emulsion foundation, wax foundation, and spray may be formulated, but are not limited thereto. In more detail, it may be prepared in the form of a flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
- the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component. .
- lactose When the formulation is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane/butane Or a propellant such as dimethyl ether.
- a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 -Butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
- a liquid diluent such as water, ethanol or propylene glycol as a carrier component, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose , Aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.
- the formulation is a surfactant containing cleansing
- aliphatic alcohol sulfate aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate , Alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanolin derivative or ethoxylated glycerol fatty acid ester, and the like may be used.
- the present invention also provides a feed composition for preventing or improving inflammatory diseases comprising an ethanol fraction of an ethanol extract of Apios Americana tubers.
- the feed composition may contain a feed additive.
- the feed additive of the present invention corresponds to an auxiliary feed in the feed management law.
- feed used in the present invention may mean any natural or artificial diet, one meal meal, etc., or a component of the one meal meal, for animals to eat, ingest, and digest.
- the kind of feed is not particularly limited, and feed commonly used in the art may be used.
- Non-limiting examples of the feed include vegetable feeds such as grains, root fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, meals or grain by-products; Animal feeds such as proteins, inorganic logistics, oils and fats, minerals, oils and fats, single-cell proteins, zooplanktons or foods. These may be used alone or in combination of two or more.
- the term “individual” means any animal (eg, human, horse, pig, rabbit, dog, sheep, goat, non-human primate, cow, Cats, guinea pigs or rodents). These terms do not refer to a particular age or gender. Accordingly, it is intended to include adult/adult and newborn subjects, whether female/female or male/male, as well as fetuses.
- Patient refers to a subject suffering from a disease or disorder. The term patient includes human and veterinary subjects.
- the term "individual in need thereof” may include healthy healthy subjects.
- the term "individual in need thereof” refers to a healthy normal individual or alcoholic gastritis. This should be interpreted as encompassing underived entities.
- the effect of the ethanol fraction of the ethanol extract of Apios americana tuber and the description of the composition including the route of administration, the number of administration, the dosage, etc. are the same as described above. Therefore, the description is omitted.
- the present invention also provides a method for preparing a fraction of Apios americana tuber extract comprising the following steps:
- the Apios americana tuber of step a) may be dried through a conventional drying method such as natural drying or hot air drying.
- the kind of extraction solvent used to extract the Apios americana tubers in step b) is ethanol.
- Ethanol extraction ie, alcohol extraction
- 50(v/v)% to 90(v/v)% ethanol more preferably 60(v/v)% to 80(v/v)% ethanol, most preferably 65(v/v) )% to 75 (v/v)% ethanol can be used as an extraction solvent.
- the method of extracting the extract of step c) is not particularly limited, and may be extracted according to a method commonly used in the art.
- Non-limiting examples of the extraction method include immersion extraction, hot water extraction, ultrasonic extraction, filtration, reflux extraction, and the like, which may be performed alone or in combination of two or more methods.
- an extract was prepared using immersion extraction.
- a solvent extract can be prepared by extracting Apios americana tubers at least once using the solvent and extraction method, and a dry extract obtained by freeze drying or spray drying after distilling the solvent extract under reduced pressure is used. Can be manufactured.
- the system fraction of step d) may be performed by flash chromatography, and preferably, a column filled with a weak basic anion exchange resin, for example, a dia-ion HP20 resin Using flash chromatography.
- the ethanol of step d) is ethanol at a concentration of 5 (v/v)% to 35 (v/v)%, and 10 (v/v)% to 30 (v/v)% ethanol , Most preferably 15 (v/v)% to 25 (v/v)% ethanol.
- Fractions prepared by the preparation method of the present invention are 2'-hydroxy-5-methoxygenistein-7,4'- O- ⁇ -D-diglucopyranoside, 2'-hydroxygenistein-7,4' -O - ⁇ -D-diglucopyranoside, 2′-hydroxygenistein-7- O - ⁇ -D-genthiobioside and 7,2′,4′-trihydroxy-5-methoxyiso It contains at least one selected from the group consisting of flavone-4′- O- ⁇ -D-glucopyranoside, and exhibits excellent anti-inflammatory activity as these four effective compounds are contained in high concentration.
- the Apios Americana tuber used in the present invention was purchased from a farm in Sacheon, Gyeongsangnam-do. After pulverizing 8.5 kg of dried Apios Americana tubers, immersion extraction was performed with 85 L of 70 (v/v)% ethanol at 40° C. for 15 hours twice. After the extract was filtered on a filter paper, the filtrate was concentrated and dried using a rotary vacuum concentrator, and finally, 1.7 kg of dried Apios americana tuber extract was obtained.
- the NO production inhibitory activity of the Apios americana extract prepared in Example 1-1 was evaluated in LPS-induced RAW 264.7 cells.
- LPS-induced RAW 264.7 cells (Korea Cell Line Bank) were plated on a 96-well plate at a density of 0.9 ⁇ 10 5 cells/mL and cultured for 24 hours. Accumulated nitrite, an indicator of NO production in the culture medium, was measured according to the Griess reagent.
- the culture supernatant was mixed with the grease reagent for 10 minutes, and then the absorbance at 540 nm was measured in a microplate reader (Molecular Devices Inc., USA). Fresh culture medium was used as a blank for all experiments, l- N 6 -(1-iminoethyl)-lysine (NIL) was used as a positive control, and the amount of nitrite in the sample was determined by referring to the sodium nitrite standard curve.
- NIL l- N 6 -(1-iminoethyl)-lysine
- the Apios americana tuber extract exhibited an IC 50 value of >100 ⁇ g/ml.
- the subfraction B08 (2.1 g) was separated by connecting two SNAP Ultra C 18 120 g cartridges (Biotage, Sweden) with a flash chromatography system (Biotage, Selekt, Sweden) (water-methanol, 90:10-60 :40), 18 subfractions (B0801-B0818) were obtained.
- the lower fraction B0803 (44.0 mg) was separated by flash chromatography system by connecting four SNAP 10 g cartridges filled with Sephadex LH-20 resin (MilliporeSigma, USA) (water-methanol, 30:70), and compound 1 (2.8 mg) was obtained.
- the isolated compound is 2′-hydroxy-5-methoxygenistein-7,4′- after comparing the spectroscopic analysis data including NMR ( 1 H and 13 C NMR) and LC/MS with the previously reported paper data.
- O - ⁇ -D-diglucopyranoside (2′-hydroxy-5-methoxygenistein-7,4′- O - ⁇ -D-diglucopyranoside; compound 1 ), 2′-hydroxygenistein-7,4′- O - ⁇ -D- gluconic di nose Llano side (2'-hydroxygenistein-7,4'- O - ⁇ -D-diglucopyranoside; compound 2), 2'-hydroxy-genistein -7- O - ⁇ -D- Zen Thiobioside (2′-hydroxygenistein-7- O- ⁇ -D-gentiobioside; compound 3 ) (Ichige, M.; Fukuda, E.; Miida, S.; Hattan, J.-i.; Misawa, N.
- Compound 4 is a new structure 7,2′,4 '- trihydroxy-5-methoxy isoflavone -4'- O - ⁇ -D- gluconic nose side pyrano (7,2', 4'-trihydroxy- 5-methoxyisoflavone-4'- O - ⁇ -D- It was identified as glucopyranoside; compound 4 ).
- Example 2 In order to evaluate the anti-inflammatory activity of the four active compounds identified in Example 2, the NO production inhibitory activity according to the treatment of each compound was confirmed in the same manner as in Example 1-2.
- each of the four compounds showed an IC 50 of 0.42 to 0.71 ⁇ M, showing excellent anti-inflammatory activity.
- Example 3 In order to prepare a fraction containing as a main component 4 kinds of compounds showing excellent anti-inflammatory activity identified in Example 3, a sample of 20.0 g of the apiose ethanol extract prepared in Example 1-1 was taken, and Diaion HP20 resin was added as a filler. Then, three kinds of Apios Americana fractions having different mobile phase solvent compositions were finally prepared by loading the cartridge column and applying it to a flash chromatography system. The flash chromatography system was performed under the conditions of Table 2 below, and the elution amount, yield and yield according to the solvent composition of the mobile phase are shown in Table 3.
- Example 1-2 In the same manner as in Example 1-2, the activity of inhibiting NO generation according to the fraction treatment was confirmed.
- sample IC 50 ( ⁇ g/ml) 100(v/v)% water fraction >100 20(v/v)% ethanol fraction 38.52 ⁇ 9.16 100 (v/v)% ethanol fraction >100
- Figure 4 shows all samples on the same scale, in Apios americana tuber ethanol extract (A), the ratio of inactive primary metabolites such as starch is high, and the active fraction, 20 (v/v)% ethanol fraction (C) It can be seen that the peak for the active ingredient having the included anti-inflammatory activity appears very weak.
- the proportion of the raw material ethanol extract (A) is very high (weight yield: 84.8(w/w)%), but inert substances dissolved in water and eluted Most of them, as materials without a UV chromophore, did not appear on the HPLC detector (UV detector).
- the active compounds contained in the ethanol extract (A) are 20 (v/v)% ethanol fraction (C ), and in the case of the 100(v/v)% water fraction (B), the scale is too enlarged and it can be seen that it looks exaggerated unlike the actual one.
- the active compounds contained in the 20(v/v)% ethanol fraction (C) were identified as compounds 1 to 4, and these 4 types of active compounds were contained in a high content to provide excellent anti-inflammatory effect and prevention or treatment of alcoholic gastritis It is judged to be effective.
- the effect of improving alcoholic gastritis was evaluated using a 20 (v/v)% ethanol fraction, which contained 4 kinds of active compounds at a high concentration and had the best NO inhibitory activity.
- mice Seven week old C57BL/6 mice were purchased from Dooyeol Biotech. The light/dark cycle at 23°C was set at 12-hour intervals, and diet and water were freely supplied to adapt to the basic diet for one week.
- mice were divided into 4 groups as shown in Table 7 to conduct the experiment.
- the ethanol fraction was orally administered to mice at different concentrations (50 mg/kg/day or 200 mg/kg/day), and gastritis was induced with HCl/EtOH after fasting for 12 hours.
- the experimental samples were dissolved in ethanol (5.0 g/kg) and administered orally once.
- the animals were anesthetized with ether, and heart blood was collected and gastric tissue was removed after opening.
- the gastric tissues extracted from each group were fixed to observe the extent and extent of damage. As shown in FIG. 7A, in the case of the gastritis-induced group administered with only HCl/EtOH, inflammation, bleeding, redness, and swelling of the stomach tissue occurred, resulting in damage to the gastric mucosa, and the area of the injury site was also very large. This gastric tissue damage was significantly recovered in a concentration-dependent manner in the experimental group treated with the 20(v/v)% ethanol fraction.
- Tissues were fixed in 10% NBF for 24 hours for histopathological analysis. After paraffin embedding, 3-4 ⁇ m sections were prepared, and hematoxylin & eosin (H&E) staining and PAS staining were performed for examination with an optical microscope. As shown in FIGS. 7B and 7C, it was confirmed that the degree of damage and morphological deformation of the gastric mucosa were improved to a level similar to that of the normal group. In addition, in the gastritis-induced group, the mucous layer protecting the mucous membrane was lost by HCl/EtOH, but a distinctly stained mucus layer was observed in the fraction administration group.
- H&E hematoxylin & eosin
- the gastric tissue was separated, the internal mucosa of the stomach was washed with 0.9% NaCl, expanded, and photographed using an optical digital camera, and the damage area was measured using the image J program. Calculated.
- the gastritis-inducing group exhibited a high ulcer index of 16.736 ⁇ 3.70 due to gastric mucosa damage caused by HCl/EtOH stimulation, but in the ethanol fraction treatment group, the degree of mucosal damage was significantly dependent on concentration. It was reduced, and in particular, at the concentration of 200 mg/kg/day, it showed an improvement effect of more than 60%.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
La présente invention concerne l'utilisation d'une fraction d'un extrait de tubercule d'Apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production. Plus précisément, la présente invention concerne : une composition anti-inflammatoire contenant une fraction de tubercule d'Apios americana extraite et fractionnée avec un solvant spécifique ; une composition, contenant la composition anti-inflammatoire, pour prévenir, améliorer ou traiter une maladie inflammatoire ou une gastrite alcoolique ; un procédé de prévention ou de traitement d'une maladie inflammatoire ou d'une gastrite alcoolique utilisant la composition anti-inflammatoire ; une utilisation d'une fraction éthanol d'un extrait éthanolique de tubercule d'Apios americana dans la production d'un agent anti-inflammatoire ou d'un médicament pour prévenir ou traiter une maladie inflammatoire ou une gastrite alcoolique ; et un procédé de production de la fraction ayant une activité anti-inflammatoire.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0073024 | 2019-06-19 | ||
KR20190073024 | 2019-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020256464A1 true WO2020256464A1 (fr) | 2020-12-24 |
Family
ID=74040296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/007962 WO2020256464A1 (fr) | 2019-06-19 | 2020-06-19 | Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102457802B1 (fr) |
WO (1) | WO2020256464A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114377044A (zh) * | 2021-12-01 | 2022-04-22 | 山东省农业科学院 | 一种芹菜籽提取物的制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230094888A (ko) * | 2021-12-21 | 2023-06-28 | 한국 한의학 연구원 | 아피오스 아메리카나 괴경 추출물을 포함하는 알코올성 간 손상 또는 알코올 뇌 손상 보호용 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120038321A (ko) * | 2010-10-13 | 2012-04-23 | 전남과학대학 산학협력단 | 아피오스를 이용한 화장료 조성물 및 이의 제조방법 |
KR20150132616A (ko) * | 2014-05-15 | 2015-11-26 | 주식회사 피토메카 | 아피오스 추출물 또는 아피오스 발효 추출물을 유효성분으로 포함하는 면역증강용 조성물 |
KR20190020889A (ko) * | 2017-08-22 | 2019-03-05 | 안동대학교 산학협력단 | 아피오스 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
-
2020
- 2020-06-19 KR KR1020200074975A patent/KR102457802B1/ko active IP Right Grant
- 2020-06-19 WO PCT/KR2020/007962 patent/WO2020256464A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120038321A (ko) * | 2010-10-13 | 2012-04-23 | 전남과학대학 산학협력단 | 아피오스를 이용한 화장료 조성물 및 이의 제조방법 |
KR20150132616A (ko) * | 2014-05-15 | 2015-11-26 | 주식회사 피토메카 | 아피오스 추출물 또는 아피오스 발효 추출물을 유효성분으로 포함하는 면역증강용 조성물 |
KR20190020889A (ko) * | 2017-08-22 | 2019-03-05 | 안동대학교 산학협력단 | 아피오스 추출물을 유효성분으로 함유하는 혈전증의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 |
Non-Patent Citations (2)
Title |
---|
HYO-YOUNG KIM, JANG KIM, YANGKANG SO, SI-YONG KANG, HYE JEONG, CHANG JIN: "Anti-Inflammatory Effect of Lupinalbin A Isolated from Apios americana on Lipopolysaccharide-Treated RAW264.7 Cells", MOLECULES, vol. 23, no. 3, pages 583, XP055767230, DOI: 10.3390/molecules23030583 * |
YOUNG HYE SEO, JU-HYUN JEON, MIRAN JEONG, SEUNG MOK RYU, WON KYUNG JEON, DAE SIK JANG, SANG HEE SHIM, DONGHO LEE, JUNG-HYE CHOI, J: "Chemical Constituents of Apios americana Tubers and Their Inhibitory Activities on Nitric Oxide Production in Lipopolysaccharide-Stimulated RAW 264.7 Macrophages", JOURNAL OF NATURAL PRODUCTS, AMERICAN CHEMICAL SOCIETY, US, vol. 81, no. 7, 27 July 2018 (2018-07-27), US, pages 1598 - 1603, XP055767231, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.8b00182 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114377044A (zh) * | 2021-12-01 | 2022-04-22 | 山东省农业科学院 | 一种芹菜籽提取物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20200145757A (ko) | 2020-12-30 |
KR102457802B1 (ko) | 2022-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012074183A1 (fr) | Composition pharmaceutique pour prévenir ou traiter des maladies inflammatoires comprenant un extrait de trachelospermi caulis et un extrait de paeonia suffruticosa andrews, et son procédé de préparation | |
WO2020246777A1 (fr) | Procédé de préparation d'un extrait de fruit noni riche en iridoïde ou d'une fraction de celui-ci, procédé de préparation d'extrait de fruit noni riche en matière active d'amélioration immunitaire ou fraction de celui-ci et utilisation d'un extrait de fruit noni ou d'une fraction de celui-ci | |
WO2016060525A1 (fr) | Composition contenant un extrait ou une fraction d'une plante du genre justicia | |
WO2020256464A1 (fr) | Utilisation d'une fraction d'extrait de tubercule d'apios americana ayant une activité anti-inflammatoire comme agent préventif ou thérapeutique de la gastrite alcoolique, et son procédé de production | |
WO2018212531A1 (fr) | Composition pharmaceutique pour la prévention ou le traitement de la démence et l'amélioration de la fonction cognitive, comprenant un extrait de salicorne | |
WO2017073849A1 (fr) | Composition pour la prévention ou le traitement de l'arthrite, contenant un extrait de sargassum serratifolium en tant que substance active | |
WO2020242113A1 (fr) | Composition pour la prévention, le soulagement ou le traitement du syndrome métabolique accompagné de l'obésité et/ou du diabète, contenant, en tant que principe actif, un complexe (complexe ib) d'extrait de groseille indienne et d'extrait d'orge jeune | |
WO2021080297A1 (fr) | Composition contenant un extrait de fleur d'onagre en tant que principe actif pour prévenir ou traiter l'obésité ou des syndromes métaboliques ainsi induits | |
WO2016010340A1 (fr) | Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation | |
WO2022045418A1 (fr) | Aliment fonctionnel de santé, comprenant un extrait de chrysanthème de sibérie, pour le soulagement de la douleur ou l'antioxydation | |
WO2017099509A1 (fr) | Composition pour le traitement ou la prévention de maladies du foie contenant comme principe actif un extrait de sicyos angulatus | |
WO2013012117A1 (fr) | Utilisation de compositions pharmaceutiques comprenant un phytostérol pour prévenir ou traiter les maladies inflammatoires | |
WO2015167240A1 (fr) | Composition contenant un extrait de scutellaria alpina | |
WO2018106009A1 (fr) | Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires | |
WO2015194809A1 (fr) | Composition à effet immunomodulateur et immunostimulant comprenant un extrait de dendropanax morbifera léveille en tant que principe actif, et son utilisation | |
WO2021261660A1 (fr) | Procédé de préparation d'extrait de farine d'huile de sésame et composition alimentaire le comprenant en tant que principe actif pour la prévention ou le soulagement de la colite | |
WO2014065640A2 (fr) | Composition pour le traitement ou la prévention de maladies inflammatoires contenant un extrait de myagropsis myagroides ou fraction de celui-ci comme principe actif | |
WO2021002642A1 (fr) | Composition pour prévenir ou traiter la polyarthrite rhumatoïde, comprenant du venin de serpent | |
WO2021080298A1 (fr) | Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière | |
WO2012105816A2 (fr) | Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci | |
WO2020204479A1 (fr) | Composition pour soulager des troubles de la circulation veineuse comprenant un extrait de feuille de raisin et un extrait de centella asiatica | |
WO2016003120A1 (fr) | Composition de blanchiment comprenant un extrait de scutellaria alpina | |
WO2015152653A1 (fr) | Composition comprenant un extrait de feuilles de génépi blanc | |
WO2015105373A1 (fr) | Composition pour la prévention ou le traitement de l'asthme, comprenant un extrait de l'e uonymus alatus ou une fraction de ce dernier | |
WO2016117762A1 (fr) | Composition contenant un extrait de groseille à maquereau ou du glutathion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20826112 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20826112 Country of ref document: EP Kind code of ref document: A1 |